

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-31. (Cancelled)

32. (Currently Amended) ~~The A method of Claim 28 further~~ for inhibiting growth of a cell that overexpresses ErbB2, the method comprising:

- a) exposing -a the cell to an isolated first antibody that binds SEQ ID NO:2 of ErbB2, wherein said binding induces apoptosis of said cell; and
- b) subsequently exposing the cell to a second anti-ErbB2 antibody that ~~does not bind~~ binds ErbB2 at an epitope other than SEQ ID NO:2 epitope 7C2/7F3 (SEQ ID NO:2) of ErbB2.

33. (Currently Amended) The method of Claim ~~28~~ 32, ~~further comprising exposing the cell to a~~ wherein said second antibody ~~that binds ErbB2 and~~ inhibits growth of SKBR3 cells in cell culture by 50-100%.

34. (Currently Amended) The method of Claim ~~33~~ 32, wherein the cell is exposed to the first antibody before the cell is exposed to the second antibody.

35. (Currently Amended) The method of Claim ~~33~~ 32, wherein the second antibody binds epitope 4D5 (SEQ ID NO:4) on ErbB2.

36. (Currently Amended) The method of Claim ~~35~~ 32, wherein the second antibody has complementarity determining regions (CDRs) of antibody 4D5.

37-38. (Cancelled)

39. (Currently Amended) The method of Claim ~~28~~ 32, further comprising exposing the cell to radiation.

40-42. (Cancelled)

43. (Currently Amended) The method of Claim ~~42~~32, wherein the cell is a cancer cell.

44-50. (Cancelled)

51. (Currently Amended) The method of Claim 28 wherein the antibody is humanized 7C2.

52-65. Cancelled.